A detailed history of Strategy Asset Managers LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Strategy Asset Managers LLC holds 10,744 shares of BMY stock, worth $583,614. This represents 0.09% of its overall portfolio holdings.

Number of Shares
10,744
Holding current value
$583,614
% of portfolio
0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

BUY
$40.25 - $52.99 $432,446 - $569,324
10,744 New
10,744 $446,000
Q2 2023

Aug 24, 2023

BUY
$63.71 - $70.74 $43,641 - $48,456
685 Added 6.81%
10,744 $687,000
Q1 2023

May 02, 2023

BUY
$65.71 - $74.53 $660,976 - $749,697
10,059 New
10,059 $697,000
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $3.69 Million - $4.08 Million
-82,625 Closed
0 $0
Q1 2019

May 08, 2019

SELL
$45.12 - $53.8 $625,182 - $745,452
-13,856 Reduced 14.36%
82,625 $3.94 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $1.04 Million - $1.35 Million
-21,299 Reduced 18.08%
96,481 $5.02 Million
Q3 2018

Nov 01, 2018

SELL
$55.19 - $62.25 $768,410 - $866,706
-13,923 Reduced 10.57%
117,780 $0
Q2 2018

Aug 07, 2018

SELL
$50.53 - $62.98 $454 - $566
-9 Reduced 0.01%
131,703 $7.29 Million
Q1 2018

May 03, 2018

BUY
$59.92 - $68.98 $610,584 - $702,906
10,190 Added 8.39%
131,712 $8.33 Million
Q4 2017

Jan 29, 2018

BUY
$59.94 - $65.35 $1.04 Million - $1.13 Million
17,337 Added 16.64%
121,522 $7.45 Million
Q3 2017

Nov 06, 2017

SELL
$55.23 - $63.74 $153,649 - $177,324
-2,782 Reduced 2.6%
104,185 $6.64 Million
Q2 2017

Aug 07, 2017

BUY
N/A
106,967
106,967 $5.96 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Strategy Asset Managers LLC Portfolio

Follow Strategy Asset Managers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategy Asset Managers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategy Asset Managers LLC with notifications on news.